A peer-reviewed article just published in the Annals of Medicine titled "Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic" describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.
A new study just published in the Journal of Medical Economics found that the FebriDx® test could save the UK healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.
Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients
Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients
Lumos Diagnostics, a point-of-care diagnostic test developer, manufacturer and marketer, secured U.S. $15 million in Series A funding from Planet Innovation, an Australia-based healthtech innovation and commercialization company.
Lumos Diagnostics received the Biomarkers Award at the recent 2019 UK Diagnostics Summit in Manchester, England for FebriDx®, a rapid POC test.
Lumos Diagnostics, a previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged.
Webinar: How advances in rapid point-of-care technologies are enabling ultra-high sensitivity detection of biomarkers
In this presentation, Lumos Diagnostics and nanoComposix explore technological advances in next generation nanoparticles, assay chemistries, and reader devices to improve the performance of rapid point-of-care (POC) tests.
Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.